Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection
HCV-TARGET Study Group
Internal Medicine
Int Med - Digestv & Liver Dis
Research output
:
Contribution to journal
›
Article
›
peer-review
153
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Simeprevir
100%
Sofosbuvir
90%
Ribavirin
70%
Hepacivirus
57%
Sustained Virologic Response
52%
Genotype
44%
Infections
29%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
12%
Observational Studies
12%
telaprevir
11%
Fibrosis
11%
Cohort Studies
10%
Therapeutics
10%
Logistic Models
10%
Selection Bias
8%
North America
8%
Sleep Initiation and Maintenance Disorders
8%
Protease Inhibitors
8%
Exanthema
7%
Duration of Therapy
7%
Interferons
7%
Nausea
6%
Headache
6%
Fatigue
6%
RNA
5%
Demography
5%
Guidelines
5%
Weights and Measures
4%
Confidence Intervals
4%
Safety
4%